GlassScriptPhysician profile
Maria Pico
NPI 1326044744
$6,917.68
in general payments reported to CMS, 2019-2025
32 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $459 · 2021: $974 · 2022: $1,018 · 2023: $1,139 · 2024: $1,250 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,277 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,276.81 |
| Education | $126.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,286.53 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $867.17 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $706.09 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $632.98 | 2019-2024 | Winlevi |
| Novartis Pharmaceuticals Corporation | $550.96 | 2019-2025 | |
| Lilly USA, LLC | $505.91 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $408.45 | 2019-2022 | |
| Incyte Corporation | $394.67 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $288.52 | 2023-2025 | Zoryve |
| Genzyme Corporation | $185.67 | 2020-2025 | |
| Amgen INC. | $174.59 | 2020-2025 | Enbrel, Otezla, Otezla |
| Leo Pharma INC. | $110.60 | 2019-2025 | Spevigo, Adbry |
| Revance Therapeutics, INC. | $101.49 | 2024 | Daxxify |
| Ucb, INC. | $95.71 | 2024-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $74.81 | 2019-2023 | Siliq, Targretin, Jublia |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $67.88 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $56.97 | 2020-2023 | |
| Ani Pharmaceuticals, INC. | $53.80 | 2025 | Sovuna |
| Almirall LLC | $44.78 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $40.57 | 2023 | |
| Dusa Pharmaceuticals, INC. | $35.41 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $35.21 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $28.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.46 | 2025 | Spevigo |
| Galderma Laboratories, L.P. | $23.18 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $20.75 | 2024 | Sotyktu |
| Sandoz INC. | $20.45 | 2020 | |
| Merz North America, INC. | $19.83 | 2019 | |
| Allergan, INC. | $17.85 | 2022 | |
| Dermira, INC. | $16.85 | 2019 | |
| Botanix Sb INC | $14.83 | 2025 | Sofdra |
| Organon LLC | $11.82 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Pico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.